Interferon-mediated activation of the STAT signaling pathway in a human carcinoid tumor

Annals of Surgical Oncology

Volumn 5, Issue 7, 1998, Pages 642-649

  Wang, Shan ^b   Tyring, Stephen K ^a   Townsend Jr , Courtney M ^a   Evers, B Mark ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Endocrine tumors; Interferon; Signal transduction pathways; Stat proteins

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON;

ARTICLE; CARCINOID; ELECTROPHORETIC MOBILITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PANCREAS CANCER; PROTEIN DNA BINDING; SIGNAL TRANSDUCTION;

EID: 0031756403     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303835     Document Type: Article

References (48)

1. Modlin IM, Sandor A, An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-29.
2. Maurer CA, Baer H-U, Dyong TH, et al. Carcinoid of the pancreas: clinical characteristics and morphological features. Eur J Cancer 1996;32A:1109-16.
3. Ahlman H. The role of surgery in patients with advanced midgut carcinoid tumours. Digestion 1996;57:86-7.
4. Arnold R, Frank M. Control of growth in neuroendocrine gastroenteropancreatic tumours. Digestion 1996;57:69-71.
5. Oberg K, Eriksson B, Janson ET. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion 1994;55: 64-9.
6. Evers BM, Hurlbut SC, Tyring SK, Townsend CM Jr, Uchida T, Thompson JC. Novel therapy for the treatment of human carcinoid. Ann Surg 1991;213:411-6.
7. Grandér D, Xu B, Einhorn S. Cytotoxic effect of Interferon on primary malignant tumour cells. Studies in various malignancies. Eur J Cancer 1993;29A:1940-3.
8. Collins T, Korman AJ, Wake CT, et al. Immune Interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA 1984;81:4917-21.
9. Philip R, Epstein LB. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γinterferon and interleukin-1. Nature 1986;323:86-9.
10. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994:264:1415-21.
11. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK/STAT pathway. Annu Rev Biochem 1995; 64:621-51.
12. Yamanaka Y, Nakajima K, Fukada T, Hibi M, Hirano T. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J 1996:15:1557-65.
13. WAF1/CIP1 mediated by Stall. Science 1996;272:719-22.
14. Marra F, Choudhury GG, Abboud HE. Interferon-γ-mediated activation of Statl α regulates growth factor-induced mitogenesis. J Clin Invest 1996:98:1218-30.
15. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu X-Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 1997:17:5328-37.
16. Muli AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J 1996;15: 2425-33.
17. Buer J, Kirchner H, Schomburg A, et al. Cytokine-based biotherapy of gastrointestinal tumors. Clin Invest 1994;72:526-34.
18. Evers BM, Townsend CM Jr, Upp JR Jr, et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991;101:302-11.
19. Parekh D, Ishizuka J, Townsend CM Jr, et al. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 1994;9:83-90.
20. Schreiber E, Matthias P, Müller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts,' prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
21. Wang S, Wolf SE, Evers BM. Differential activation of the Stat signaling pathway in the liver after burn injury. Am J Physiol 1997;273(Gastroiotest Liver Physiol 36):G1153-9.
22. Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J 1990;9:4477-84.
23. Zhong Z, Wen Z, Darnell JE Jr. Slat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-8.
24. Mui AL-F, Wakao H, O'Farrell A-M, Harada N, Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two Stat5 homologs. EMBO J 1995;14:1166-75.
25. Woll PJ, Pettengell R. Interferons in oncology. Br J Clin Pract 1997:51:111-5.
26. Oberg K, Funa K, Alm G. Effects of leukocyte Interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129-33.
27. 2b in patients with endocrine active tumours. Ear J Cancer 1992;28A:1664-6.
28. Oberg K. Interferon-α versus somatostatin or the combination of both in gastro-enteropancreatic tumours. Digestion 1996;57:81-3.
29. Pestka SJ, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Am Rev Biochem 1987;56:727-77.
30. Gutterman JU. Cytokine therapeutics: lessons from interferon α. Proc Natl Acad Sci USA 1994;91:1198-205.
31. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grandér D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-α in hematopoietic cell lines. Cell Growth Differ 1997;8:343-52.
32. Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ. Differential human multiple myeloma cell line responsiveness to interferon-α. Analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 1997; 99:447-56.
33. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon α and interferon γ. Proc Natl Acad Sci USA 1996;93:7673-8.
34. Yu C-R, Lin J-X, Fink DW, Akira S, Bloom ET, Yamauchi A. Differential utilization of Janus kinase-signal transducer and activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-α J Immunol 1996;157:126-37.
35. Yang C-H, Shi W, Basu L, et al. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J Biol Chem 1996;271:8057-61.
36. Meinke A, Barahmand-Pour F, Ẅhrl S, Stoiber D, Decker T. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol 1996; 16:6937-44.
37. Raz R, Durbin JE, Levy DE. Acute phase response factor and additional members of the interferon-stimulated gene factor 3 family integrate diverse signals from cytokines, interferons, and growth factors. J Biol Chem 1994;269:24391-5.
38. Lewis GD, Aggarwal BB, Eessalu TE, Sugarman BJ, Shepard HM. Modulation of the growth of transformed cells by human tumour necrosis factor-α and interferon-γ. Cancer Res 1987;47:5382-5.
39. Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH. Immunomodulatory and immunotherapeutic properties of recombinant γ-interferon and recombinant tumor necrosis factor in mice. Cancer Res 1987;47:2563-70.
40. Osanto S, Jansen R, Vloemans M. Downmodulation of c-myc expression by interferon γ and tumour necrosis factor α precedes growth arrest in human melanoma cells. Eur J Cancer 1992;28A: 1622-7.
41. Sokoloff MH, Tso C-L, Kaboo R, Taneja S, Pang S, deKernion JB, Belldegrun AS. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 1996;77:1862-72.
42. Paolo AD, Bocci G, Innocenti F, Agen C, Nardini D, Danesi R, Tacca MD. Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines. Pharmacol Res 1995;32:135-9.
43. Marth C, Helmberg M, Mayer I, Fuith LC, Daxenbichler G, Dapunt O. Effects of biological response modifiers on ovarian carcinoma cell lines. Anticancer Res 1989;9:461-8.
44. Tanson JE, Kauppinen HL, Oberg K. Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. Acta Oncol 1993;32:231-3.
45. Smit LS, Meyer DJ, Billestrup N, Norstedt G, Schwartz J, CarterSu C. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH. Mol Endocrinol 1996;10:519-33.
46. Barahmand-pour F, Meinke A, Kieslinger M, Eilers A, Decker T. A role for STAT family transcription factors in myeloid differentiation. Curr Top Microbiol Immunol 1996;211:121-8.
47. Liu X, Robinson GW, Hennighausen L. Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol 1996;1496-1506.
48. WAF1/cip1 by STAT5. Mol Cell Biol 1997;17:2933-43.